ArticleAntimicrobial agents and chemotherapy2018
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
Open access · bronzeAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed, 1 synthesis or guideline pooled it, 281 citations in OpenAlex.
- A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.The Journal of antimicrobial chemotherapy · 2025Pooled it
- Risk factors for therapeutic failure in the management of post-operative peritonitis: a post hoc analysis of the DURAPOP trial.The Journal of antimicrobial chemotherapy · 2021Trial
- Assessing Clinical Effectiveness of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam in Bacteremia: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Risk factors forMicrobiology spectrum · 2026Article
- Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections.Antimicrobial agents and chemotherapy · 2026Article
- Characterization of prophage carrying blaEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Suboptimal ceftazidime-avibactam exposure drives sequentialMicrobiology spectrum · 2026Article
- Article
- Pharmacokinetics/pharmacodynamics of ceftazidime-avibactam in critically ill adult patients receiving continuous renal replacement therapy.Antimicrobial agents and chemotherapy · 2026Article
- Model-Informed Ceftazidime-Avibactam Dosing Stratified by Renal Function and Renal Replacement Therapy Status in Critically Ill Patients: A Prospective Population Pharmacokinetic and Monte Carlo Simulation Study.Drug design, development and therapy · 2026Article
- The changing epidemiology and long-term outcomes of patients with CRE infections.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Impact of Attaining an Aggressive Pharmacokinetic-Pharmacodynamic Target on the Clinical Efficacy of Continuous Infusion β-Lactam Therapy for Early Posttransplant Gram-Negative Infections in Critically Ill Orthotopic Liver Transplant Recipients: An Interim Analysis of a 3-Year Prospective, Observational Study.The Journal of infectious diseases · 2025Observational
- Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistantAntimicrobial agents and chemotherapy · 2025Article
- Validation of a predictive risk score of aggressive PK/PD target non-attainment with continuous infusion piperacillin/tazobactam or meropenem in critically ill patients having documented Gram-negative infections.Journal of anesthesia, analgesia and critical care · 2025Article
- Ceftazidime-Avibactam: A Retrospective Analysis of Multicenter Real-World Data and Factors Affecting Mortality.Infectious diseases & clinical microbiology · 2025Article
- Feasibility analysis of pharmacy practice based on the evidence-based pharmacy model in the treatment of patients with severe pneumonia.Pakistan journal of medical sciences · 2025Article
- β-Lactam/β-Lactamase Inhibitor Combinations in Sepsis-Associated Acute Kidney Injury and Renal Replacement Therapy.Antibiotics (Basel, Switzerland) · 2025Review
- Ceftazidime-Avibactam Resistance in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Emergence of ceftazidime-avibactam resistance in clinical Klebsiella pneumoniae during therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Ceftazidime-Avibactam in Critically Ill Patients: A Multicenter Observational Study.Antibiotics (Basel, Switzerland) · 2025Article
90 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Ryan K ShieldsDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
M Hong NguyenDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA mhn5@pitt.edu.
Liang ChenPublic Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA.
Ellen G PressDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Barry N KreiswirthPublic Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA.
Cornelius J ClancyDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
University of Pittsburgh Medical Center · USRutgers, The State University of New Jersey · USUniversity of Pittsburgh · US
Funding
The molecular basis of the epidemic blaKPC gene KlebsiellaR01AI090155 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI KREISWIRTH, BARRY NEAL · 2011 to 2021
$7.2MCaspofungin pharmacokinetics-pharmacodynamics during intra-adbominal candidiasisK08AI114883 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2015 to 2019
$858kEvolution of KPC-K pneumoniae that persist in patients on prolonged antibioticsR21AI111037 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CLANCY, CORNELIUS J · 2015 to 2016
$465kChromosomal and plasmid contributions to colistin resistance and virulence in KPC-producing Klebsiella pneumoniaeR21AI128338 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NGUYEN, M. HONG THI · 2017 to 2018
$444kGenomic variation in epidemic carbapenem-resistant K.pneumoniaeR21AI117338 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI CHEN, LIANG · 2016 to 2017
$437kNIAID NIH HHS K08 AI114883NIAID NIH HHS R01 AI090155NIAID NIH HHS R21 AI111037NIAID NIH HHS R21 AI117338NIAID NIH HHS R21 AI128338
Abstract
Ceftazidime-avibactam was used to treat 77 patients with carbapenem-resistant
Indexed as
AdultAgedAged, 80 and overAzabicyclo CompoundsCarbapenem-Resistant EnterobacteriaceaeCeftazidimeDrug CombinationsEnterobacteriaceae InfectionsFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedPneumoniaRenal Replacement TherapyRisk Factorsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCeftazidimeDrug Combinationsceftazidime-avibactamCREfailureKlebsiella pneumoniaeoutcomespneumoniarenal replacement therapy
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.